DICYCLOMINE (dye SYE kloe meen) treats irritable bowel syndrome (IBS). It works by relaxing the muscles of your stomach and bowel, which reduces cramping. It belongs to a group of medications called antispasmodics. Technically, dicyclomine is a tertiary amine with anticholinergic and antimuscarinic activity that antagonizes peripheral muscarinic receptors in the enteric nervous system, reducing smooth muscle spasms and gastrointestinal motility and decreasing secretions. It is available as the hydrochloride salt in oral and parenteral formulations; typical adult oral dosing is in the range of 10 to 20 mg given three to four times daily depending on formulation and clinical guidance. Pharmacokinetic features include prompt oral absorption, hepatic metabolism to multiple polar metabolites, and renal elimination of metabolites. Analytical and formulation considerations include stability of the hydrochloride salt, control of pH in liquid forms, and methods for assay and impurity profiling using HPLC with UV or MS detection.
Parent: Dicyclomine
Parent: Dicyclomine
Manufacturers and quality laboratories control related substances using validated chromatographic methods such as HPLC and GC and follow ICH guidance for reporting and qualification thresholds. Common related compounds and process impurities include N-dealkylated and desethyl metabolites, N-oxide variants, residual starting materials such as cyclohexyl-phenyl alcohol intermediates, and process-related amine byproducts; residual solvents from synthesis are controlled to ICH Q3C limits. Typical specification strategies set individual unidentified impurity limits in the low parts-per-thousand to parts-per-ten-thousand range; for example, individual related compounds are often limited to below 0.1 to 0.5 percent and total impurities are commonly controlled to below about 1.0 to 2.0 percent, with tighter limits applied when required by monographs or regulatory authorities. Identification, structural elucidation and control strategies are used for any impurity exceeding identification or qualification thresholds based on maximum daily dose.
Dicyclomine is used to relieve smooth muscle spasms in the gastrointestinal tract and to reduce cramping associated with irritable bowel syndrome and other functional bowel disorders; it is prescribed to reduce spasm-related symptoms rather than to treat underlying inflammation or infection.
No, dicyclomine is not an analgesic in the classical sense; it reduces pain that arises from intestinal muscle spasms by blocking muscarinic receptors and relaxing smooth muscle, but it does not act on central pain pathways like opioid or nonsteroidal analgesics.
Dicyclomine can decrease intestinal motility and may reduce cramping and urgency that accompany diarrhea in some cases, but it is not primarily an antidiarrheal agent for infectious or secretory diarrhea and should not replace standard antidiarrheal therapy when indicated.
No, dicyclomine is not an antibiotic and has no activity against bacteria or other pathogens; it addresses muscle spasms and symptoms but does not treat infections.
